挽救性局灶治疗与根治性前列腺切除术治疗局限性放疗后复发性前列腺癌的比较
这项国际多中心匹配队列研究比较了挽救性局灶治疗(sFT)与挽救性根治性前列腺切除术(sRP)在局限性放疗后复发性前列腺癌患者中的肿瘤控制与围手术期并发症。结果显示两组10年癌症特异性生存率无统计学显著差异,但sRP与任何并发症和重大并发症的 odds 显著更高相关。sFT可能为许多此类患者提供有利的治疗比。
要点
- sRP与任何并发症(aOR 24.20)和重大并发症(aOR 9.31)的 odds 显著更高相关。
- sFT可能为局限性放疗后复发性前列腺癌患者提供更好的治疗比。
核心结论
- 在局限性放疗后复发性前列腺癌患者中,sFT与sRP均有效,但sFT与更少的围手术期并发症相关。
- sFT可能为许多此类患者提供有利的治疗比。
研究设计与样本
- 国际多中心匹配比较队列研究,sFT患者来自前瞻性UK HIFU和International Cryotherapy Evaluation登记(9中心,2006-2024)及UK Focal Recurrent Assessment and Salvage Treatment队列(6中心,2014-2018),sRP患者来自国际回顾性登记(8国12中心,2000-2021)。
- 共923例患者符合匹配条件(sFT 419例,sRP 504例),采用1:1 cardinality matching在多重插补数据集内进行匹配。
- 匹配变量包括放疗类型、原发与挽救治疗间隔年数、EAU复发风险组、挽救前年龄、PSA、前列腺体积、分级组、T分期和ADT使用。
临床怎么用
- 对于局限性放疗后复发性前列腺癌患者,sFT可作为与sRP肿瘤控制相当但围手术期并发症更少的选择。
- 临床决策时可结合患者具体情况,考虑sFT以降低围手术期并发症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with recurrent prostate cancer after previous radiotherapy typically have poor survival. Those with recurrences prostate confined might be suitable for salvage focal therapy (sFT) or salvage radical prostatectomy (sRP). sFT may offer good cancer control with comparatively less toxic effects, but outcomes beyond 5 years have not been reported, and no study has compared sFT to sRP. OBJECTIVE: To compare cancer control and perioperative complications among patients after sFT vs sRP. DESIGN, SETTING, AND PARTICIPANTS: In this international, multicenter cohort study of matched comparison data, patients undergoing sFT were derived from the prospective UK HIFU (high-intensity focused ultrasound) Evaluation and Treatment and International Cryotherapy Evaluation registries (9 centers; 2006-2024) and the prospective UK Focal Recurrent Assessment and Salvage Treatment cohort study (6 centers; 2014-2018). Patients undergoing sRP were derived from an international retrospective registry (12 centers in 8 countries; 2000-2021). Patients with biopsy-confirmed, localized recurrent prostate cancer postradiotherapy, either external beam radiotherapy, brachytherapy, or both, were included. Data were analyzed from March to July 2025. EXPOSURES: sFT using HIFU or cryotherapy vs sRP. MAIN OUTCOMES AND MEASURES: The primary outcome was cancer-specific survival up to 10 years. Secondary outcomes were overall survival, any perioperative complications (Clavien-Dindo grades 1-5), and major perioperative complications (Clavien-Dindo grades 3-5). Comparisons were made on matched patients following 1:1 cardinality matching within individual multiply-imputed datasets. Matching variables used were radiotherapeutic treatment, years between primary and salvage treatments, European Association of Urology recurrence risk group, and presalvage age, prostate-specific antigen, prostate volume, grade group, T stage, and androgen-deprivation therapy use. RESULTS: A total of 923 patients were eligible for matching (419 undergoing sFT and 504 undergoing sRP). Of the patients undergoing sFT, 325 (77.6%) underwent HIFU and the remainder cryotherapy, with 241 (57.5%) treated with quadrant ablation. Of patients treated with sRP, 376 (74.6%) underwent open surgery and the remainder robot-assisted surgery. For sFT vs sRP, 10-year cancer-specific survival was 92% (95% CI, 86%-98%) vs 99% (95% CI, 97%-100%), with no statistically significant difference (restricted mean time lost, -0.09 years; 95% CI, -0.22 to 0.03 years; P = .15; subdistribution hazard ratio, 0.45; 95% CI, 0.05-4.00; P = .47). There was no statistically significant difference in 10-year overall survival (restricted mean survival time, -0.13 years; 95% CI, -0.86 to 0.60 years; P = .72). Undergoing sRP was associated with statistically significant higher odds of any complication (adjusted odds ratio, 24.20; 95% CI, 12.94-45.27; P < .001) and major complication (adjusted odds ratio, 9.31; 95% CI, 3.42-25.36; P < .001). CONCLUSIONS AND RELEVANCE: In this cohort study, sFT and sRP were effective for treating localized radiorecurrent prostate cancer, while sFT was associated with fewer perioperative complications. sFT may provide a favorable therapeutic ratio for many patients with localized radiorecurrent prostate cancer.
引用
- Light A, Peters M, Arya M, et al. Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer. JAMA Oncol. 2026. PMID: 41678176. doi:10.1001/jamaoncol.2025.6448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。